Great West Life Assurance Co. Can held its position in Repligen Corp. (NASDAQ:RGEN) during the second quarter, Holdings Channel reports. The firm owned 3,900 shares of the company’s stock at the end of the second quarter. Great West Life Assurance Co. Can’s holdings in Repligen Corp. were worth $104,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the stock. First Manhattan Co. raised its position in Repligen Corp. by 42.8% in the first quarter. First Manhattan Co. now owns 14,275 shares of the company’s stock valued at $382,000 after buying an additional 4,275 shares in the last quarter. Virginia Retirement System bought a new position in Repligen Corp. during the first quarter valued at approximately $381,000. TIAA CREF Investment Management LLC raised its position in Repligen Corp. by 26.3% in the first quarter. TIAA CREF Investment Management LLC now owns 203,734 shares of the company’s stock valued at $5,464,000 after buying an additional 42,400 shares during the period. BlackRock Group LTD raised its position in Repligen Corp. by 6.3% in the first quarter. BlackRock Group LTD now owns 49,515 shares of the company’s stock valued at $1,328,000 after buying an additional 2,915 shares during the period. Finally, BlackRock Fund Advisors raised its position in Repligen Corp. by 0.7% in the first quarter. BlackRock Fund Advisors now owns 2,457,356 shares of the company’s stock valued at $65,906,000 after buying an additional 16,941 shares during the period. 89.38% of the stock is currently owned by institutional investors and hedge funds.
Repligen Corp. (NASDAQ:RGEN) traded up 3.39% during trading on Friday, reaching $30.54. The company had a trading volume of 284,727 shares. The company has a market capitalization of $1.03 billion, a P/E ratio of 122.16 and a beta of 1.29. Repligen Corp. has a 12 month low of $20.07 and a 12 month high of $36.00. The stock has a 50 day moving average of $31.83 and a 200-day moving average of $27.62.
Repligen Corp. (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.03. The firm had revenue of $29.20 million for the quarter, compared to analyst estimates of $24.75 million. Repligen Corp. had a return on equity of 10.74% and a net margin of 8.69%. Repligen Corp.’s quarterly revenue was up 35.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.11 earnings per share. Equities research analysts expect that Repligen Corp. will post $0.44 EPS for the current fiscal year.
Several research firms recently commented on RGEN. Zacks Investment Research raised Repligen Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. Jefferies Group reissued a “hold” rating and set a $28.00 price target on shares of Repligen Corp. in a research report on Monday, June 13th.
In related news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $32.58, for a total transaction of $87,966.00. Following the transaction, the director now directly owns 9,394 shares of the company’s stock, valued at $306,056.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.30% of the company’s stock.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corp. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.